



+

KRChoksey Institutional

India Equity	Institutional R	esearch II Re	sult Update – Q1FY22	ll 29 th July 2021	Page 2
Granu	les India	a Ltd.		Strong growth slows down b	out should revive from H2FY22
CMP INR 372	Target INR 459	Potential Upside 23.4 %	Market Cap (INR M INR 92,040	n) Recommendation BUY	Sector Pharmaceuticals

Result Highlights of Q1FY22

• Granules India reported revenue growth of 15.5% YoY (+6.3% QoQ) to INR 84,985 Lakhs in Q1FY22 mainly on account of new launches and increase in market share of existing products.

- The company faced challenges in the quarter, such as shortage of raw materials, and lower utilization in capacities, especially in Paracetamol, and logistic disruption.
- Gross margin declined 300 bps QoQ and 530 bps YoY to 54.2% in Q1FY22.
- Consequently, EBITDA grew 9.7% YoY (-0.3% QoQ) to INR 20,143 Lakhs in Q1FY22; however, EBITDA margin contracted to 23.7% in Q1FY22 (-126 bps YoY / -157 bps QoQ).
- Net Profit grew 7.9% YoY; however, declined 5.8% QoQ to INR 12,020 Lakhs.

к

MARKET DATA	
Shares outs (Mn)	248.7
Equity Cap (INR Mn)	21,733
Mkt Cap (INR Mn)	92,040
52 Wk H/L (INR)	438/271
Volume Avg (3m K)	3,496
Face Value (INR)	1
Bloomberg Code	GRAN

EY FINANCIALS							
INR Mn	FY19	FY20	FY21	FY22E	FY23E		
Revenue	22,792	25,986	32,375	36,791	44,908		
EBITDA	3,840	5,253	8,552	8,302	10,354		
PAT	2,364	3,354	5,495	5,685	7,129		
Adj PAT	2,364	3,077	5,495	5,685	7,129		
EPS (INR)	9.3	13.2	21.6	22.4	28.0		
Adj. EPS (INR)	9.30	12.10	21.61	22.36	28.04		
EBITDA Margin (%)	16.8%	20.2%	26.4%	22.6%	23.1%		
NPM (%)	10.4%	12.9%	17.0%	15.5%	15.9%		

QoQ growth in Q1FY22, after two consecutive quarters of lower to mid single negative

growth, sequentially. The YoY growth has slowed down on account of high base effect, apparently due to high growth in API in Q1FY21. The growth in revenue in Q1FY22 was driven by new launches and increase in market shares of existing products. The company continues

to face supply challenges in sourcing their key starting material (KSM), such as para –

aminophenol, leading to lower utilization of their API capacity. Nevertheless, the company

GPM contracted due to Paracetamol related challenges and lower demand for few products


and EBITDA declined due to higher other expenses: Gross margin contracted 300 bps QoQ and 530 bps YoY to 54.2% in Q1FY22. This was largely due to reduction in margins of Paracetamol as its key raw material's prices increased. Similarly, EBITDA margins contracted 126 bps YoY and 157 bps QoQ to 23.7% in Q1FY22. This was due to lower GPMs due to lower

profitability for Paracetamol, driven by shortage of raw materials. It was also caused by higher other expenses due to higher logistics costs. The company, consequently, posted a muted growth in net income by 7.9% YoY (-5.8% QoQ) to INR 12,020 lakhs. This was weak, as despite a 132.5% QoQ and 35.4% YoY rise in other income to INR 762 lakhs, and a flat interest

ensures that the supply challenges are easing up to benefit from Q3FY22 onwards.

Source: Company, KRChoksey Research Revival in QoQ revenue growth visible in Q1FY22:. The company posted 15.5% YoY and 6.3%

SHARE PRICE PERFORMANCE



MARKET INFO

SENSEX	52,444
NIFTY	15,709

expenses QoQ, the company posted subdued growth numbers. **New product filings and launches:** The company filed 1 ANDA, 2 EU dossiers, and one South African dossier during Q1FY22 vs. 6 ANDA , 1 EU dossier and 1 Canadian dossier approved in Q4FY21. Also, the company received one ANDA approval and launched one ANDA in the US in Q1FY22. In total there remain 21 products pending approvals while 46 are approved including 2 tentatively approved products across US, Europe, Canada, South Africa and UK as of Q1FY22. R&D spend was INR 2.27 Cr in Q1FY22 vs. INR 20 Cr in FY21. The same is expected to be around INR 140-150 Cr by the end of FY22.

SHARE HOLDING PATTERN (S	٤)
--------------------------	----

Particulars	Jun-21 (%)	Mar-21 (%)	Dec-20 (%)
Promoters	42.0	42.0	42.0
FIIs	18.4	23.3	26.4
DIIs	2.9	1.3	0.3
Others	36.7	33.4	31.3
Total	100	100	100

17.8%

Revenue CAGR between FY21 and FY23E 13.9%

PAT CAGR between FY21 and FY23E

KRChoksey Research is also available on Bloomberg KRCS<GO> Thomson Reuters, Factset and Capital IQ India Equity Institutional Research II

Result Update – Q1FY22

Key Concall Highlights: : (i) The company believes the shortage in supply of its key raw material for Paracetamol is easing up in Q2FY22 as domestic production has ensued with one supplier, another supplier is to start the production of it in a few months, and China is resuming supply, can help the company to return to normalcy by H2FY22 (ii) The company has been expanding its formulations segment sales by foraying into new geographies as the company has approvals for 2 of its existing products in Europe and that the company awaits approvals for filed products as well as continues to file more. (iv) The company is close to signing and out-licensing with a few companies in Europe for approved products. (v) The company bagged an approval for one product each in Latin America and Canada, which were launched through partners as it plans to anew expand in geographies such as Canada, Latin America, and South Africa, going forward. (vi) The company envisions that new products apart from their existing four molecules will contribute 40% of revenue by FY25 (vii) the company's US based unit, Granules Pharmaceuticals had a pre-approval inspection by USFDA recently and received the EIR within 25 days of completion of the inspections.

Valuation and view: Granules India is facing challenges owing to supply disruption in API segment, that we believe is likely to cause higher loss in profitability than in revenue over FY22-FY23. In the wake of likely margin headwinds to be faced in FY22, we downgrade our Revenue/EBITDA growth estimates over FY21E-FY23E to 18% and 10% CAGR, respectively, (vs. earlier forecast of 21.8% and 14.6% CAGR, respectively, during FY21 - FY23E). Since our last update on the company, the shares have risen by ~14% though. The stock is trading at a forward P/E multiple of 16.6x/13.3x on FY22E/FY23E earnings. We apply a P/E multiple of 16.4x on FY23E EPS of INR 28.0 (earlier 16x on FY23E EPS of INR 28.4) and maintain our target price of INR 459/ share as we believe the company is facing temporary headwinds due to supply constraints and can revive its financials from H2FY22 onwards. As the Target Price gives an upside of 23.4% over the CMP of INR 372, we reiterate our "BUY" rating on the shares of Granules India.

Geography Wise Results (INR Mn)	Q1FY21	Q2FY21	Q3FY21	Q4FY21	Q1FY22
Revenue from operations	7,356	8,581	8,445	7,993	8,498
North America	3,814	4,719	4,359	4,556	4,513
Europe	1,405	1,536	1,572	1,159	1,428
India	842	1,183	1,420	1,079	1,173
Latin America	862	658	696	711	926
Rest of World	433	485	398	488	459
Geographic Mix (%)	Q1FY21	Q2FY21	Q3FY21	Q4FY21	Q1FY22
Revenue from operations	100%	100%	100%	100%	100%
North America	52%	55%	52%	57%	53%
Europe India	19% 11%	18%	19%	15%	17%
Latin America	11%	14% 8%	17% 8%	14% 9%	14% 11%
Rest of World	6%	6%	5%	<u> </u>	5%
Geography Wise Performance (% YoY)	Q1FY21	Q2FY21	Q3FY21	Q4FY21	Q1FY22
Revenue from operations	23.6%	22.7%	20.0%	33.2%	15.5%
North America	26.8%	27.7%	17.0%	32.1%	18.3%
Europe	8.8%	9.0%	5.4%	34.1%	1.6%
India	10.5%	18.9%	37.3%	7.5%	39.3%
Latin America	70.7%	13.1%	36.7%	40.9%	7.5%
Rest of World	11.6%	54.5%	42.7%	178.6%	6.0%
Segment Result (INR Mn)	Q1FY21	Q2FY21	Q3FY21	Q4FY21	Q1FY22
Revenue from operations	7,356	8,581	8,445	7,990	8,500
Active Pharmaceutical Ingredients (API)	3,856	2,547	2,518	1,940	2,240
Pharmaceutical formulation ingredients (PFI)	1,379	1,733	1,706	1,440	1,720
Finished Dosage (FD)	2,121	4,301	4,221	4,610	4,540
Segment Mix (%)	Q1FY21	Q2FY21	Q3FY21	Q4FY21	Q1FY22
Total Revenue	100%	100%	100%	100%	100%
Active Pharmaceutical Ingredients (API)	52%	30%	30%	24%	26%
Pharmaceutical formulation ingredients (PFI)	19%	20%	20%	18%	20.2%
Finished Dosage (FD)	29%	50%	50%	58%	53%
Segment Performance (% YoY)	Q1FY21	Q2FY21	Q3FY21	Q4FY21	Q1FY22
Total Revenue	23.6%	22.7%	20.0%	33.2%	15.6%
Active Pharmaceutical Ingredients (API)	35.2%	17.2%	20.4%	9.2%	-41.9%
Pharmaceutical formulation ingredients (PFI)	42.0%	32.6%	47.7%	84.4%	24.7%
Finished Dosage (FD)	-0.4%	22.4%	11.3%	34.0%	114.0%
Source: Company, KRChoksey Research	•• •••	22• 7 /0	» <i>ر</i> وانا	יידע	11-0/0

ANAI YST

Parvati Rai, head-research@krchoksey.com, +91-22-66965413

KRChoksey Research is also available on Bloomberg KRCS<GO> Thomson Reuters, Factset and Capital IQ Phone: +91-22-6696 5555, Fax: +91-22-6691 9576 www.krchoksey.com

Equity Institutional Research II Result Update – Q1FY22 II 29 th July 202
--

KEY FINANCIALS

Exhibit 1: Profit & Loss Statement

INR Mn	FY19	FY20	FY21	FY22E	FY23E
Revenues	22,792	25,986	32,375	36,791	44,908
COGS	13,610	14,179	15,427	18,265	22,075
Gross profit	9,182	11,808	16,948	18,525	22,833
Employee cost	2,098	3,007	4,082	4,597	5,612
Other expenses	4,298	4,917	5,829	7,098	8,664
EBITDA	3,840	5,253	8,552	8,302	10,354
EBITDA Margin	16.8%	20.2%	26.4%	22.6%	23.1%
Depreciation & amortization	1,055	1,370	1,515	1,472	1,796
EBIT	2,786	3,884	7,038	6,830	8,557
Interest expense	285	270	263	258	242
Other income	267	366	269	290	290
Share of Associates & JV	487	255	0	0	0
РВТ	3,255	4,511	7,044	6,863	8,606
Тах	891	1,157	1,549	1,177	1,477
Exceptional items	0	-277	0	0	0
PAT	2,364	3,354	5,495	5,685	7,129
Adj. PAT	2,364	3,077	5,495	5,685	7,129
EPS (INR)	9.3	13.2	21.6	22.4	28.0

Exhibit 2: Cash Flow Statement

INR Mn	FY19	FY20	FY21	FY22E	FY22E
Net Cash Generated From Operations	2,622	4,762	4,325	4,809	3,211
Net Cash Flow from/(used in) Investing Activities	-2,698	-1,606	-2,771	-2,881	-2,683
Net Cash Flow from Financing Activities	-174	-2,129	-2,993	-469	-640
Net Inc/Dec in cash equivalents	-250	1,027	-1,440	1,460	-112
Opening Balance	1,080	830	1,859	418	1,878
Closing Balance Cash and Cash Equivalents	830	1,859	418	1,878	1,766

Source: Company, KRChoksey Research

Exhibit 3: Key Ratios

Key Ratio	FY19	FY20	FY21	FY22E	FY23E
EBITDA Margin (%)	16.8%	20.2%	26.4%	22.6%	23.1%
Tax rate (%)	27.4%	25.7%	22.0%	17.2%	17.2%
Net Profit Margin (%)	10.4%	12.9%	17.0%	15.5%	15.9%
RoE (%)	15.5%	18.2%	25.3%	21.0%	21.1%
RoCE (%)	11.3%	14.7%	24.1%	19.7%	20.6%
EPS (INR)	9.3	13.2	21.6	22.4	28.0

Source: Company, KRChoksey Research

Page 4

Exhibit 4: Balance Sheet NR Mn	FY19	FY20	FY21	FY22E	FY23E
Non-current assets					
Property, plant and equipment	7,476	9,888	10,712	13,288	14,410
Capital work-in-progress	3,235	1,481	2,391	2,391	2,391
Intangible assets	3,691	3,613	2,608	2,608	2,608
Financial assets	<i>Ji</i> - <i>J</i> .	515	_,	_,	_,
Investments	2,104	193	190	190	190
Loans	169	166	131	131	131
Deferred Tax Assets	42	53	8	74	91
Income Tax Assets (Net)	17	5	57	8	9
Other non-current assets	271	597	1,068	846	1,033
Total non-current assets	17,006	15,997	17,164	19,535	20,862
Current assets				51555	,
Inventories	3,842	4,384	7,822	6,005	7,258
Financial assets		1/2 1	.,	, ,	
Trade receivables	6,735	7,352	7,654	9,072	14,149
Cash and cash equivalents	830	1,859	418	1,878	1,766
Other Balances with Banks	60	980	2,292	2,292	2,292
Loans	32	79	100	100	100
Other financial assets	5	36	6	51	62
Other current assets	1,318	2,328	1,678	3,296	4,023
Total current assets	12,822	17,018	19,970	22,694	29,650
TOTAL ASSETS	29,828	33,015	37,135	42,229	50,513
				., ,	
EQUITY AND LIABILITIES					
Equity					
Equity share capital	254	254	248	248	248
Other equity	15,040	18,183	21,485	26,853	33,584
Total equity	15,295	18,437	21,733	27,101	33,832
LIABILITIES					
Non-current liabilities					
Financial liabilities					
Borrowings	4,788	4,215	3,411	4,300	4,300
Deferred tax liabilities, (net)	655	482	11	683	833
Provisions	126	215	248	248	248
Total non-current liabilities	5,569	4,912	3,671	5,231	5,382
Current liabilities					
Financial liabilities					
Borrowings	4,542	3,717	4,093	3,310	3,310
Trade payables	3,235	4,300	5,410	4,254	5,141
Other financial liabilities	1,019	1,360	1,806	1,926	2,351
Other current liabilities	117	171	202	242	296
Provisions	43	60	68	84	103
Income tax liabilities, (net)	9	57	152	81	99
		9,665	11,731	9,897	11,299
Total current liabilities	0,905	9,005	119/31	9,09/	11,299
Total current liabilities Total liabilities	8,965 14,533	14,578	15,402	15,128	16,681

Source: Company, KRChoksey Research

5

India Equity Institutional Research II	Result Update – Q1FY22	ll 29 th July 2021	Page 6

Granules India Ltd.		Rating Legend (Expected over a 12-month period)			
Date	CMP (INR)	TP (INR)	Recommendation	Our Rating	Upside
29-Jul-21	372	459	BUY		opside
30-Jun-21	325	459	BUY	Buy	More than 15%
12-May-21	337	459	BUY		
17-Mar-21	331	459	BUY	Accumulate	5% – 15%
15-Dec-21	338	459	BUY	Hold	o
21-Oct-20	386	459	BUY	Ηοία	0 – 5%
20-Jun-20	265	314	BUY	Reduce	-5% – 0
03-Jun-20	181	229	BUY		
22-Apr-20	159	199	BUY	Sell	Less than – 5%

ANALYST CERTIFICATION:

I, Parvati Rai (MBA-Finance, M.com), Head Research, author and the name subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect my views about the subject issuer(s) or securities. I also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Terms & Conditions and other disclosures:

KRChoksey Shares and Securities Pvt. Ltd (hereinafter referred to as KRCSSPL) is a registered member of National Stock Exchange of India Limited and Bombay Stock Exchange Limited. KRCSSPL is a registered Research Entity vides SEBI Registration No. INH000001295 under SEBI (Research Analyst) Regulations, 2014.

We submit that no material disciplinary action has been taken on KRCSSPL and its associates (Group Companies) by any Regulatory Authority impacting Equity Research Analysis activities.

KRCSSPL prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analyst covers. The information and opinions in this report have been prepared by KRCSSPL and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of KRCSSPL. While we would endeavor to update the information herein on a reasonable basis, KRCSSPL is not under any obligation to update the information. Also, there may be regulatory, compliance or other reasons that may prevent KRCSSPL policies, in circumstances where KRCSSPL might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. KRCSSPL will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. KRCSSPL accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Succepts no liabilities whatsoever for any loss or damage of any kind arising out of the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Our employees in sales and marketing team, dealers and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed herein, .In reviewing these materials, you should be aware that any oral of the foregoing, among other things, may give rise to real o

Associates (Group Companies) of KRCSSPL might have received any commission/compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of brokerage services or specific transaction or for products and services other than brokerage services.

KRCSSPL or its Associates (Group Companies) have not managed or co-managed public offering of securities for the subject company in the past twelve months.

KRCSSPL encourages the practice of giving independent opinion in research report preparation by the analyst and thus strives to minimize the conflict in preparation of research report. KRCSSPL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither KRCSSPL nor Research Analysts have any material conflict of interest at the time of publication of this report.

It is confirmed that, Parvati Rai (MBA-Finance, M.com), Head Research of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months. Compensation of our Research Analysts is not based on any specific brokerage service transactions.

KRCSSPL or its associates (Group Companies) collectively or its research analyst do not hold any financial interest/beneficial ownership of more than 1% (at the end of the month immediately preceding the date of publication of the research report) in the company covered by Analyst, and has not been engaged in market making activity of the company covered by research analyst.

It is confirmed that, Parvati Rai (MBA-Finance, M.com), Head Research do not serve as an officer, director or employee of the companies mentioned in the report.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other Jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject KRCSSPL and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform them of and to observe such restriction.

Please send your feedback to research.insti@krchoksey.com Visit us at www.krchoksey.com KRchoksey Shares and Securities Pvt. Ltd Registered Office: 1102, Stock Exchange Tower, Dalal Street, Fort, Mumbai – 400 001. Phone: +91-22-6533 8060. Corporate Office: ABHISHEK, 5th Floor, Link Road, Andheri (W), Mumbai – 400 053. Phone: +91-22-6696 5555; Fax: +91-22-6699 5576.

KRChoksey Research is also available on Bloomberg KRCS<GO> Thomson Reuters, Factset and Capital IQ Phone: +91-22-6696 5555, Fax: +91-22-6691 9576 www.krchoksey.com